Löfgren syndrome is an acute, self-limiting form of sarcoidosis defined by a recognizable cluster of symptoms: painful red skin nodules (erythema nodosum), swollen lymph nodes visible on a chest X-ray, joint inflammation (usually at the ankles), and often fever. First described in 1946 by the Swedish physician Sven Löfgren, the condition stands apart from other forms of sarcoidosis because it tends to resolve on its own and carries a generally favorable prognosis, though the details are more interesting than that simple reassurance suggests.
The Classic Triad and Its Variations
Textbooks describe Löfgren syndrome as a triad: erythema nodosum, bilateral hilar lymphadenopathy (enlarged lymph nodes at the center of both lungs), and acute arthritis, often accompanied by fever.1Reumatología Clínica. The classic triad of Löfgren’s syndrome in images In practice, not every patient presents with all three features. A study of 80 patients across two university hospitals found that only about 60% had the full triad. Roughly a quarter had hilar lymphadenopathy plus arthritis without the skin rash, and about 17% had lymphadenopathy plus erythema nodosum without joint symptoms.2Annals of the Rheumatic Diseases. A Look at Löfgren Syndrome: 80 Cases in Two Universitary Hospitals So while the triad is the hallmark, “incomplete” presentations are common enough that clinicians have to keep Löfgren syndrome in mind even when one piece of the puzzle is missing.
Erythema nodosum, the skin component, shows up as tender, reddish-purple lumps typically on the shins, though they can appear on the forearms and elsewhere. These nodules result from inflammation in the fat layer beneath the skin, not from granulomas (the tiny clusters of immune cells that define sarcoidosis at a tissue level). They tend to be painful and warm to the touch, and they can be alarming if you don’t know what they are, since the legs can look badly bruised.
Who Develops Löfgren Syndrome
Löfgren syndrome follows many of the same demographic patterns as sarcoidosis broadly, but with some differences. It affects women more than men and is most common in people of Scandinavian descent. Other groups with higher sarcoidosis incidence include people of African American, Afro-Caribbean, Irish, Puerto Rican, and North African backgrounds, though the link to Löfgren syndrome specifically is strongest in Scandinavians.3IntechOpen. Löfgren’s Syndrome The average age of onset is around 39, roughly eight years younger than for sarcoidosis in general.
One curious feature is a seasonal pattern. Cases cluster in the spring and early summer. An analysis of 87 patients found that presentations peaked in May and dropped to their lowest in January and November, a pattern that was statistically significant and that also varied somewhat by age and sex.4PubMed. Analysis of 87 patients with Löfgren’s syndrome and the pattern of seasonality of subacute sarcoidosis This spring-summer clustering has led researchers to suspect environmental triggers, possibly airborne antigens like pollen, mold spores, or other seasonal exposures that provoke an immune response in genetically susceptible individuals. No single trigger has been definitively identified, but the seasonality is consistent enough to reinforce the idea that Löfgren syndrome results from a particular type of immune overreaction to something in the environment.
What Is Actually Happening in the Ankles
Ankle pain and swelling are so central to Löfgren syndrome that they’re often the symptom that drives a person to seek medical attention in the first place. But here’s where things get counterintuitive: in most cases, the problem isn’t actually inside the ankle joint. Ultrasound studies have shown that the swelling around the ankles is predominantly periarthritis, meaning inflammation of the tissues surrounding the joint rather than within the joint cavity itself.
In one study using musculoskeletal ultrasound, about 72% of patients did not have the classic signs of acute joint inflammation (capsule distension and increased blood flow within the joint). Only a quarter had any ankle joint fluid at all, and when it was present it was almost always mild. Instead, what the ultrasound revealed in the vast majority of cases was extensive swelling in the soft tissue beneath the skin, consistent with periarthritis rather than true arthritis.5PubMed. Evaluation of ankle swelling due to Lofgren’s syndrome: a pilot study using B-mode and power Doppler ultrasonography About 39% also showed inflammation of the tendon sheaths. Another ultrasound study confirmed bilateral tenosynovitis of the flexor tendons with inflamed subcutaneous tissue, again without significant joint effusion or synovitis.6PubMed Central. High-resolution ultrasound of the ankles in Lofgren syndrome: attention to detail may be the key to diagnosis
This distinction matters practically. When someone presents with severely swollen, painful ankles and a red rash on their legs, it can be mistaken for cellulitis (a skin infection) or gout. In fact, case reports describe patients initially treated with antibiotics for presumed cellulitis before the correct diagnosis was made.7PubMed Central. Lofgren’s Syndrome: A Unique Presentation of Sarcoidosis Masquerading as Lower Extremity Cellulitis Understanding that the swelling is periarticular rather than articular can help distinguish Löfgren syndrome from conditions that cause true joint effusions.
How Löfgren Syndrome Is Diagnosed
Diagnosis rests primarily on recognizing the clinical pattern. When someone presents with erythema nodosum, bilateral hilar lymphadenopathy, and ankle periarthritis (with or without fever), the combination is distinctive enough that many clinicians consider it diagnostic without a tissue biopsy. A chest X-ray showing symmetrically enlarged lymph nodes at the lung hila is often the imaging finding that clinches the diagnosis.8PubMed Central. Löfgren Syndrome: Clinical Presentation, Clinical Course, and Literature Review CT scanning may be added to look for additional findings like mediastinal lymphadenopathy or small lung nodules, especially when the picture is less clear-cut.9European Medical Journal. Acute Form of Sarcoidosis (Löfgren Syndrome): A Case Report
When the presentation is incomplete or when there’s diagnostic uncertainty, a biopsy becomes more important. Bronchoscopy with bronchoalveolar lavage can show an elevated CD4-to-CD8 ratio in the lung fluid, and tissue samples may reveal the noncaseating granulomas that define sarcoidosis histologically.10PubMed Central. Lofgren’s Syndrome: A Unique Presentation of Sarcoidosis Masquerading as Lower Extremity Cellulitis “Noncaseating” means the granulomas don’t have the cheese-like center seen in tuberculosis, which is a key distinction because tuberculosis is one of the main conditions that can mimic Löfgren syndrome. Lymphoma is the other major differential that needs to be excluded, since bilateral hilar lymphadenopathy can also be caused by certain blood cancers.11PubMed Central. Lofgren Syndrome: Achieving an Accurate Diagnosis for Improved Patient Care
Blood tests play a supporting role. Angiotensin-converting enzyme (ACE) levels are often checked, but only about 15% of Löfgren syndrome patients have elevated ACE, making it a poor screening tool. That said, those with elevated ACE tend to have more persistent arthritis, so the test can carry some prognostic value even when it’s not useful for diagnosis.12Rheumatology Consultant. Lofgren Syndrome
The Genetics Behind the Good Prognosis
Löfgren syndrome’s reputation as “the good sarcoidosis” is largely earned, but the strength of that prognosis depends heavily on genetics, specifically on a single immune-system gene variant. Patients with Löfgren syndrome have strong associations with certain HLA-DRB1 alleles, and one in particular stands out: HLA-DRB1*03.13PubMed. HLA associations and Löfgren’s syndrome HLA genes help the immune system distinguish the body’s own proteins from foreign ones, and specific variants influence how a person’s immune system reacts to different triggers.
People who carry the DRB1*03 allele and develop Löfgren syndrome have an excellent outlook, with roughly 95% recovering within two years. Carrying HLA-DRB1*15, on the other hand, is linked to chronic disease.14Utrecht University. Löfgren’s syndrome: genetic associations, clinical course and outcome This is a starker genetic dividing line than you see in many inflammatory conditions. Two people can present with what looks like the same disease, and their HLA type can predict very different trajectories. In settings where HLA typing is available, it can give patients and their doctors a much clearer picture of what to expect.
Treatment
Because Löfgren syndrome is usually self-limiting, treatment focuses on managing symptoms rather than curing the underlying disease. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen are the first-line approach and provide relief for most patients. Colchicine, typically associated with gout treatment, is another option for mild cases.15Annals of Rehabilitation Medicine. Lofgren’s Syndrome-Acute Onset Sarcoidosis and Polyarthralgia: A Case Report
When symptoms are more severe or don’t respond to NSAIDs, oral corticosteroids come into play. This happens in roughly one in ten cases, typically with prednisolone at modest doses of 20 mg daily or less to push the inflammation into remission.16PubMed Central. Löfgren Syndrome: A Case Report and Treatment Challenge Some patients initially started on NSAIDs end up switching to corticosteroids when the joint symptoms prove stubborn. The response to steroids, when they’re needed, tends to be quick. That said, there is a legitimate question about whether early steroid treatment could mask the natural course of the disease or complicate the picture if a relapse occurs later, which is why most clinicians start conservatively.
Other factors associated with a longer course that might need treatment include older age at diagnosis, more advanced lung involvement at the time of initial imaging, and baseline need for treatment itself, all of which have been linked to disease persisting beyond two years.17PubMed. Sarcoidosis presenting with and without Löfgren’s syndrome: Clinical, radiological and behavioral differences observed in a group of 691patients
Long-Term Outcomes and the Relapse Question
The standard reassurance is that Löfgren syndrome resolves and doesn’t come back. That’s true for most people, but long-term follow-up data add some nuance. In a cohort followed for a median of nearly 11 years, about 11% experienced a relapse, and half of those relapses happened more than five years after the original diagnosis.18American Journal of Respiratory and Critical Care Medicine. Disease Relapse Rate from Long-Term Follow-Up Data in Löfgren’s Syndrome That’s a meaningful minority, and the timing means some patients may have considered themselves completely recovered before the disease returns.
Genetics split the relapse picture sharply. Among patients carrying HLA-DRB1*03 who relapsed, only about 38% relapsed with Löfgren syndrome again; the rest developed other forms of sarcoidosis. Among DRB1*03-negative patients who relapsed, 89% relapsed as Löfgren syndrome. Furthermore, patients who were positive for HLA-DRB1*15 were significantly more likely to develop chronic disease after a relapse.19American Journal of Respiratory and Critical Care Medicine. Disease Relapse Rate from Long-Term Follow-Up Data in Löfgren’s Syndrome These findings suggest that the genetic background not only influences the initial course of the disease but shapes what happens if it comes back. For patients without the favorable DRB1*03 allele, particularly those carrying DRB1*15, some ongoing awareness and occasional follow-up even years later may be warranted.
Löfgren Syndrome in Older Adults
Löfgren syndrome is much less common as a first presentation of sarcoidosis in older adults. A 42-year single-center study found that Löfgren syndrome was the initial presentation in roughly 42% of younger sarcoidosis patients but in only about 9% of those over 65.20Respiratory Medicine. Elderly sarcoidosis: A comparative study from a 42-year single-centre experience When sarcoidosis does appear in older adults, it tends to present differently: more advanced lung disease on imaging, more isolated organ involvement outside the lungs, and a higher rate of subcutaneous nodules. Older patients with sarcoidosis also achieved remission less often during follow-up and had higher rates of pulmonary fibrosis and sarcoidosis-related death.
This doesn’t mean an older adult can’t develop Löfgren syndrome, but it does mean the diagnosis is less likely to be on a clinician’s radar in that age group. When bilateral hilar lymphadenopathy appears in someone over 65, lymphoma and other malignancies will typically be investigated first, and reasonably so. The reassuring prognosis associated with Löfgren syndrome in younger patients should not be automatically applied to older patients with sarcoidosis, whose disease tends to behave more aggressively regardless of initial presentation.
Why the Condition Was Recognized as Distinct
Sarcoidosis is a disease that can affect virtually any organ, follow wildly different timelines, and present with symptoms ranging from a persistent cough to skin lesions to heart rhythm problems to eye inflammation. Against that backdrop, Sven Löfgren’s identification in 1946 of a specific, recognizable pattern was significant because it carved out a subgroup with a dramatically better prognosis.21PubMed Central. Sarcoidosis—The Beginning: Historical Highlights of Personalities and Their Accomplishments During the Early Years Being able to tell someone “you have this particular form of sarcoidosis, and it very likely will resolve” is qualitatively different from telling them “you have sarcoidosis,” which could mean anything from a short-lived nuisance to a progressive, organ-damaging condition.
That distinction also matters for treatment decisions. A person diagnosed with sarcoidosis broadly might be started on immunosuppressive therapy relatively early, especially if the lungs or heart are affected. But for someone with a clear Löfgren syndrome presentation and the favorable HLA-DRB1*03 genotype, aggressive immunosuppression isn’t just unnecessary — it exposes the patient to drug side effects for a disease that is already on its way out. The challenge, as with many conditions, is in the incomplete presentations and ambiguous cases, where the line between “wait and see” and “treat now” isn’t as obvious.